Intellectual Property India Publishes Patent Application for 'Glycosyl-Modified Fusion Protein, Nucleic Acid Molecule, Expression Vector, Host Cell, And Use' Filed by Kaimi Biomedicine (CHENGDU) Co. Ltd.

MUMBAI, India, June 6 -- Intellectual Property India has published a patent application (202517002997 A) filed by Kaimi Biomedicine (CHENGDU) Co. Ltd., Sichuan, China, on Jan. 13, for 'glycosyl-modified fusion protein, nucleic acid molecule, expression vector, host cell, and use.'

Inventor(s) include Shi, Yuenian; Yu, Bo; and Zhang, Bo.

The application for the patent was published on June 6, under issue no. 23/2025.

According to the abstract released by the Intellectual Property India: "A glycosyl-modified fusion protein, a nucleic acid molecule, an expression vector, a host cell, and a use. The glycosyl-modified fusion protein comprises a murine Fc variant and a polypeptide antigen; the murine Fc variant is obtained by carrying out amin...